All articles
Evidence-led research on repurposed compounds and the protocols people actually ask about — cited to primary literature and reviewed for accuracy.
Curcumin Hydrogel Prevents Postoperative Prostate Cancer Recurrence (2026)
A 2026 preclinical study in the International Journal of Pharmaceutics developed a curcumin-releasing hydrogel that, when applied after prostate cancer surgery, suppressed tumor regrowth and reduced lymph node metastasis by maintaining high local drug concentration. Animal-model evidence only.
Mebendazole Disrupts Nucleotide Metabolism in Gastric Cancer (2026)
A 2026 preclinical study shows mebendazole impairs nucleotide metabolism enzymes in gastric cancer cells, causing cell cycle arrest and antiproliferative activity comparable to 5-FU with lower toxicity to normal cells. Laboratory evidence only.
Curcumin Triggers Ferroptosis in Thyroid Cancer via GPX4 Downregulation (2026 Study)
A 2026 preclinical study shows curcumin induces ferroptosis in papillary thyroid cancer cells by downregulating GPX4, suppressing tumour growth in mice without organ toxicity.
Ivermectin for Kidney Cancer: RCC Studies & Evidence
What does ivermectin research show for kidney cancer? Compare the 2017 cell and mouse study, the 2026 RCC review and the limits of human evidence.
Antiparasitic Drugs in Stage IV Cancer: 6-Patient Case Series (Integrative Medicine, 2026)
A 2026 case series in Integrative Medicine describes 6 stage IV cancer patients who showed prolonged survival after AMA-guided antiparasitic protocols including ivermectin and mebendazole.
Ivermectin Inhibits Estrogen Receptor and HER2 Pathways in Endocrine-Resistant Breast Cancer
Researchers at Chulalongkorn University found that ivermectin significantly suppressed estrogen-induced proliferation and downregulated ER, HER2, and TGF-β pathway markers in endocrine-resistant breast cancer cells, suggesting potential as a repurposed agent to overcome hormonal therapy resistance.
Mebendazole Reprograms Oncogenic Networks Across Multiple Cancer Types
Researchers found that mebendazole at 0.7 µM reprogrammed oncogenic and tumor-suppressor networks across eight cancer cell lines, suppressing ENOX2 and MMP2 while activating RASSF1A by over 200-fold.
Ivermectin and Metformin Combination Promotes Autophagy in Breast Cancer via PI3K/AKT/mTOR Pathway
Chinese researchers found that combining ivermectin with metformin significantly inhibited MCF-7 breast cancer cell viability, migration, and invasion by suppressing PI3K/AKT/mTOR signaling and triggering autophagy.
ivermectin
The Marik Protocol: Ivermectin and Mebendazole for Cancer — Theory, Evidence, and Risks
A careful, evidence-based review of the Marik ivermectin + mebendazole cancer protocol — the proposed theory, what the human data actually shows, the dosing claims, and the real safety risks.
Fenbendazole + Photothermal Therapy Triggers Ferroptosis in Bladder Cancer (Advanced Science, 2026)
A June 2026 study in Advanced Science describes a nanoplatform combining fenbendazole with photothermal therapy to trigger ferroptosis and dual immunotherapy in orthotopic bladder cancer mouse models.
Fenbendazole
Where to Buy Fenbendazole: Quality Verification, Purity Testing & Reliable Sources 2026
How to verify fenbendazole quality and purity before purchase. Reliable sources, third-party testing, counterfeit warnings, and what to look for in 2026.
Ketogenic Diet Enhances Mebendazole Therapy in Pediatric High-Grade Glioma (Cell Reports Medicine, 2026)
A June 2026 study in Cell Reports Medicine found that a ketogenic diet acts as a metabolic vehicle that enhances mebendazole's anti-tumor effects in juvenile mouse models of high-grade glioma, allowing lower drug doses and improved survival.
Nothing here yet.